• Featured Product
  • KD/KO Validated

TDP-43 (N-terminal) Rekombinanter Antikörper

TDP-43 (N-terminal) Rekombinant Antikörper für WB, IHC, IF/ICC, IF-P, FC (Intra), IP, Cytometric bead array, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IHC, IF/ICC, IF-P, FC (Intra), IP, Cytometric bead array, Indirect ELISA

Konjugation

Unkonjugiert

CloneNo.

16A22

Kat-Nr. : 80002-1-PBS

Synonyme

TARDBP, TDP 43, TDP43, TDP-43, TAR DNA-binding protein 43



Geprüfte Anwendungen

Produktinformation

80002-1-PBS bindet in WB, IHC, IF/ICC, IF-P, FC (Intra), IP, Cytometric bead array, Indirect ELISA TDP-43 (N-terminal) und zeigt Reaktivität mit human, Maus, Ratten

Getestete Reaktivität human, Maus, Ratte
Wirt / Isotyp Kaninchen / IgG
Klonalität Rekombinant
Typ Antikörper
Immunogen TDP-43 (N-terminal) fusion protein Ag1231
Vollständiger Name TAR DNA binding protein
Berechnetes Molekulargewicht 43 kDa
Beobachtetes Molekulargewicht 43 kDa
GenBank-ZugangsnummerBC001487
Gene symbol TDP-43
Gene ID (NCBI) 23435
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Protein-A-Reinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

The TARDBP gene encodes the TDP-43 protein, initially found to repress HIV-1 transcription by binding TAR DNA. TDP-43 has since been shown to bind RNA as well as DNA, and have multiple functions in transcriptional repression, translational regulation and pre-mRNA splicing. For instance, it is reported to regulate alternate splicing of the CTFR gene. In 2006 Neumann et al. found that hyperphosphorylated, ubiquitinated and/or cleaved forms of TDP-43, collectively known as pathological TDP-43, play a major role in the disease mechanisms of ubiquitin-positive, tau- and alpha-synuclein-negative frontotemporal dementia (FTLD-U) and in amyotrophic lateral sclerosis (ALS). Proteintech's 80002-1-RR is a rabbit recombinant TDP-43 antibody recognizing N-terminal TDP-43. It recognizes the intact 43 kDa protein as well as all posttranslationally modified and truncated forms in multiple applications. Various forms of TDP-43 exist, including 18-35 kDa of cleaved C-terminal fragments, 45-50 kDa phospho-protein, 55 kDa glycosylated form, 75 kDa hyperphosphorylated form, and 90-300 kDa cross-linked form. (PMID: 17023659, 19823856, 21666678, 22193176) Recently TDP-43 has been reported to be overexpressed in triple negative breast cancer (TNBC) and it may be a potential target for TNBC diagnosis and drug design. (PMID: 29581274)

80002-1-RR antibody works well in IF experiment.